BR0116785A - Processo para a sìntese da forma v de atorvastatina e fenilboronatos como compostos intermediários - Google Patents
Processo para a sìntese da forma v de atorvastatina e fenilboronatos como compostos intermediáriosInfo
- Publication number
- BR0116785A BR0116785A BR0116785-5A BR0116785A BR0116785A BR 0116785 A BR0116785 A BR 0116785A BR 0116785 A BR0116785 A BR 0116785A BR 0116785 A BR0116785 A BR 0116785A
- Authority
- BR
- Brazil
- Prior art keywords
- atorvastatin
- phenylboronates
- intermediate compounds
- synthesizing form
- synthesizing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
"PROCESSO PARA A SìNTESE DA FORMA V DE ATORVASTATINA E FENILBORONATOS COMO COMPOSTOS INTERMEDIáRIOS". A presente invenção refere-se a um novo processo para síntese de cálcio de hemiácido R-(R*,R*)]-2-(4-fluorofenil)-B,D-diidróxi-5-(1-metiletil)3-fenil-4-[(fenilami no)carbonil]-1H-pirrol-1-heptanóico, a forma V de atorvastatina. O composto assim preparado é útil como inibidor da enzima HMGCoA redutase, sendo usado como agente hipolipidêmico e hipocolesterolêmico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2001/000006 WO2002057229A1 (en) | 2001-01-19 | 2001-01-19 | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
PCT/IN2001/000114 WO2002057274A1 (en) | 2001-01-19 | 2001-06-14 | A process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0116785A true BR0116785A (pt) | 2004-03-09 |
Family
ID=11076297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0116785-5A BR0116785A (pt) | 2001-01-19 | 2001-06-14 | Processo para a sìntese da forma v de atorvastatina e fenilboronatos como compostos intermediários |
Country Status (11)
Country | Link |
---|---|
US (1) | US6867306B2 (pt) |
EP (1) | EP1351963B1 (pt) |
JP (1) | JP2004517900A (pt) |
AT (1) | ATE478079T1 (pt) |
BR (1) | BR0116785A (pt) |
CA (1) | CA2436122A1 (pt) |
CZ (1) | CZ20031946A3 (pt) |
DE (1) | DE60142854D1 (pt) |
MX (1) | MXPA03006475A (pt) |
RU (1) | RU2269515C2 (pt) |
WO (2) | WO2002057229A1 (pt) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
EP1332130A4 (en) * | 2000-11-03 | 2004-01-21 | Teva Pharma | HEMICALCIC ATORVASTATIN FORM VII |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
CA2431068C (en) | 2000-12-27 | 2008-06-10 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of atorvastatin |
CZ20033478A3 (cs) | 2001-06-29 | 2004-10-13 | Warner@Lambertácompanyállc | Krystalické formy vápenaté soli }@�B [R@}RgŹRgB]@}@fluorofenylB@betaŹ@delta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové kyseliny }atorvastatinB |
US7074818B2 (en) | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
WO2003011826A1 (en) * | 2001-07-30 | 2003-02-13 | Dr. Reddy's Laboratories Ltd. | Crystalline forms vi and vii of atorvastatin calcium |
US7361772B2 (en) * | 2001-08-16 | 2008-04-22 | Biocon Limited | Process for the production of atorvastatin calcium |
AU2003217653A1 (en) * | 2002-02-15 | 2003-09-09 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
ES2332881T3 (es) * | 2002-02-25 | 2010-02-15 | Biocon Limited | Nuevos esteres de boranato. |
WO2004050618A2 (en) * | 2002-11-28 | 2004-06-17 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
EP1424324A1 (en) * | 2002-11-28 | 2004-06-02 | Teva Pharmaceutical Industries Limited | Crystalline form F of Atorvastatin hemi-calcium salt |
US20050182125A1 (en) * | 2003-05-16 | 2005-08-18 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
US20040248972A1 (en) * | 2003-05-16 | 2004-12-09 | Ambit Biosciences Corporation | Compounds and uses thereof |
AU2004247023A1 (en) * | 2003-05-16 | 2004-12-23 | Ambit Biosciences Corporation | Heterocyclic compounds and uses thereof |
AU2003238683A1 (en) * | 2003-05-26 | 2004-12-13 | Biocon Limited | Novel process for preparation of (6-(2-amino-ethyl)-2-aryl-(1,3,2)dioxaborinan-4-yl)- acetic esters |
US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
AU2003242989A1 (en) * | 2003-06-09 | 2005-01-04 | Biocon Limited | Novel halo-substituted active methylene compounds |
US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
CA2649054A1 (en) | 2004-05-05 | 2005-11-10 | Pfizer Products Inc. | Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid |
ES2586561T3 (es) * | 2004-07-16 | 2016-10-17 | Lek Pharmaceuticals D.D. | Productos de degradación oxidativa de atorvastatina calcio |
MX2007000765A (es) | 2004-07-20 | 2007-03-28 | Warner Lambert Co | Formas cristalinas de sal de calcio del acido (r-(r*, r*))-2- (4-fluorofenil)- beta,gama- dihidroxi-5- (1-metiletil)-3 -fenil-4-((fenilamino) (carbonil)-1ih -pirrol-1- heptanoico (2:1). |
WO2006021969A1 (en) | 2004-08-27 | 2006-03-02 | Biocon Limited | Process for atorvastatin calcium amorphous |
MX2007004722A (es) | 2004-10-28 | 2007-06-15 | Warner Lambert Co | Procedimiento para formar atorvastatina amorfa. |
EP1671947A1 (en) * | 2004-12-20 | 2006-06-21 | Ratiopharm GmbH | Process for preparing pyrrole derivatives and intermediates |
EP1705175A1 (en) * | 2005-03-24 | 2006-09-27 | ratiopharm GmbH | Process for preparing C5 products and their use for Atorvastatin synthesis |
CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
PT1957452E (pt) | 2005-11-21 | 2010-05-25 | Warner Lambert Co | Novas formas de ácido [r-(r*,r*)]-2-(4-fluorofenil)-b,b--di-hidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1h-pirrole-1-heptanóico magnésico |
US8080672B2 (en) | 2005-12-13 | 2011-12-20 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
KR100763770B1 (ko) | 2006-05-29 | 2007-10-08 | 조동옥 | 아토르바스타틴 합성에 유용한 광학활성 중간체의 제조방법 |
WO2008042876A2 (en) | 2006-10-02 | 2008-04-10 | Codexis, Inc. | Compositions and methods for producing stereoisomerically pure statins and synthetic intermediates therefor |
KR100881617B1 (ko) * | 2007-02-22 | 2009-02-17 | (주) 성운파마코피아 | 아토바스타틴 제조를 위한 중간체 및 그의 제조방법 |
KR100933172B1 (ko) | 2007-11-30 | 2009-12-21 | 씨제이제일제당 (주) | 아토르바스타틴 칼슘염의 개선된 제조방법 |
EP2075246A1 (en) | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | A process for preparation of amorphous form of atorvastatin hemi-calcium salt |
KR100850558B1 (ko) * | 2008-01-02 | 2008-08-06 | 조동옥 | 아토르바스타틴의 효율적인 제조방법 |
KR101339648B1 (ko) * | 2012-05-10 | 2013-12-09 | (주) 에프엔지리서치 | 신규한 아토바스타틴 중간체 및 이를 이용한 아토바스타틴의 제조 방법 |
CN104983702A (zh) * | 2015-07-23 | 2015-10-21 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂 |
CN111909048B (zh) * | 2020-09-07 | 2021-03-16 | 浙江宏元药业股份有限公司 | 一种多组分一锅法合成阿托伐他汀钙中间体的方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US573995A (en) * | 1896-12-29 | Automatic vehicle-brake | ||
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5216174A (en) * | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
US5245047A (en) * | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5124482A (en) * | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
US5149837A (en) * | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5094045A (en) * | 1988-07-27 | 1992-03-10 | University Of Hawaii | Termite barrier |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
JP2542941B2 (ja) * | 1990-02-02 | 1996-10-09 | チッソ株式会社 | 光学活性ヒドロキシラクトン類の製造方法 |
US5103024A (en) * | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5248793A (en) * | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
CA2049536C (en) * | 1991-05-13 | 1999-07-06 | Rawle I. Hollingsworth | Process for the preparation of 3,4-dihydroxybutanoic acid and salts thereof |
US5155251A (en) * | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
ES2167587T3 (es) * | 1995-07-17 | 2002-05-16 | Warner Lambert Co | Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina). |
TR199900191T2 (xx) * | 1996-07-29 | 1999-04-21 | Warner-Lambert Company | (S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses. |
SI20305A (sl) | 1999-08-06 | 2001-02-28 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Kristali natrijeve soli pravastatina |
EP1163203A1 (en) | 1999-03-08 | 2001-12-19 | Merck & Co., Inc. | Crystalline hydrated dihydroxy open-acid simvastatin calcium salt |
HU227840B1 (en) * | 1999-05-06 | 2012-05-02 | Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag | Intermediates of atorvastatin synthesis and process for producing them |
HU226640B1 (en) | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
JP2003514798A (ja) * | 1999-11-17 | 2003-04-22 | テバ ファーマシューティカル インダストリーズ リミティド | アトルバスタチンカルシウムの多形 |
SI20425A (sl) | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
WO2001072706A1 (en) | 2000-03-28 | 2001-10-04 | Biocon India Limited | Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
AU2002232891B2 (en) * | 2000-11-16 | 2006-12-14 | Teva Pharmaceutical Industries Ltd. | Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide |
WO2002057228A1 (en) | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
SK792004A3 (sk) | 2001-07-06 | 2005-03-04 | Teva Pharmaceutical Industries Ltd. | Syntéza a medziprodukty derivátov 3,5-dihydroxyheptánovej kyseliny |
IL159719A0 (en) | 2001-07-06 | 2004-06-20 | Teva Pharma | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives |
EP1404639A1 (en) | 2001-07-06 | 2004-04-07 | Ciba SC Holding AG | Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3,5-dihydroxy heptanoic acid derivatives, and intermediates thereof |
KR20040026705A (ko) | 2001-08-16 | 2004-03-31 | 테바 파마슈티컬 인더스트리즈 리미티드 | 스타틴의 칼슘 염 형태의 제조 방법 |
IL160077A0 (en) | 2001-08-16 | 2004-06-20 | Teva Pharma | Processes for preparing calcium salt forms of statins |
AP2004003112A0 (en) | 2002-02-14 | 2004-09-30 | Ranbaxy Lab Ltd | Formulations of atorvastatin stabilised with alkali metal additions |
-
2001
- 2001-01-19 WO PCT/IN2001/000006 patent/WO2002057229A1/en active Application Filing
- 2001-06-14 WO PCT/IN2001/000114 patent/WO2002057274A1/en active Application Filing
- 2001-06-14 DE DE60142854T patent/DE60142854D1/de not_active Expired - Lifetime
- 2001-06-14 JP JP2002557951A patent/JP2004517900A/ja active Pending
- 2001-06-14 CZ CZ20031946A patent/CZ20031946A3/cs unknown
- 2001-06-14 BR BR0116785-5A patent/BR0116785A/pt active Search and Examination
- 2001-06-14 CA CA002436122A patent/CA2436122A1/en not_active Abandoned
- 2001-06-14 AT AT01955503T patent/ATE478079T1/de not_active IP Right Cessation
- 2001-06-14 RU RU2003125647/04A patent/RU2269515C2/ru not_active IP Right Cessation
- 2001-06-14 EP EP01955503A patent/EP1351963B1/en not_active Expired - Lifetime
- 2001-06-14 US US10/466,802 patent/US6867306B2/en not_active Expired - Fee Related
- 2001-06-14 MX MXPA03006475A patent/MXPA03006475A/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
US6867306B2 (en) | 2005-03-15 |
WO2002057274A1 (en) | 2002-07-25 |
WO2002057229A1 (en) | 2002-07-25 |
US20040072893A1 (en) | 2004-04-15 |
CA2436122A1 (en) | 2002-07-25 |
RU2003125647A (ru) | 2005-02-20 |
MXPA03006475A (es) | 2004-10-15 |
JP2004517900A (ja) | 2004-06-17 |
ATE478079T1 (de) | 2010-09-15 |
EP1351963B1 (en) | 2010-08-18 |
CZ20031946A3 (cs) | 2003-12-17 |
RU2269515C2 (ru) | 2006-02-10 |
DE60142854D1 (de) | 2010-09-30 |
EP1351963A1 (en) | 2003-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0116785A (pt) | Processo para a sìntese da forma v de atorvastatina e fenilboronatos como compostos intermediários | |
UY24985A1 (es) | Formas cristalinas hidratadas de atorvastatina forma i | |
EE200300597A (et) | [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[fenüülamino)karbonüül]-1H-pürrool-1-hepta anhappe kaltsiumsoola (2:1) (atorvastatiini) kristallilised vormid | |
IL155890A0 (en) | HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE | |
EE03607B1 (et) | Vorm III kristalliline [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino)karbonüül]-1H-pürrool-1-heptaanhappe hemikaltsiumsool (atorvastatiin) | |
DK0839132T5 (da) | Fremgangsmåde til fremstilling af amorft [R-(R*,R*)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyrecalciumsalt (2:1) | |
WO2004027075A3 (en) | Chemoenzymatic methods for the synthesis of statins and stain intermediates | |
NZ527048A (en) | Crystalline forms of atorvastatin | |
EP2540704A3 (en) | Benethamine salt forms of atorvastatin | |
WO2005014539A3 (en) | Pyrrole-based hmg-coa reductase inhibitors | |
MXPA04000889A (es) | Formas cristalinas vi y vii de atorvastatina calcica. | |
WO2003050085A8 (en) | CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-HEPTANOIC ACID CALCIUM SALT (2:1) | |
TW200738624A (en) | Novel forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium | |
IL173651A0 (en) | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid | |
BRPI0417138A (pt) | n-alquil-pirroles como inibidores de hmg-coa-redutase | |
DE69616358D1 (de) | Kristalline form iii des hemi calcium salzes von [r-(r*,r*)]-2-(4-fluorphenyl)-beta-delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure (atorvastatin) | |
ZA200303974B (en) | Hydrolysis of [R(R*,R*)]-2-(4-Fluorophenyl)-b,D-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic acid esters with calcium hydroxide. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2258 DE 15/04/2014. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |